• Xue Wang, Lin Qian, Zengxing Qian, Qihang Wu, Dongying Cheng, Junjun Wei, Lingmin Song, Shuaihuai Huang, Xiaodong Chen, Ping Wang, and Guobin Weng.
• Zhejiang Key Laboratory of Pathophysiology, Ningbo University, Ningbo, China.
• Medicine (Baltimore). 2024 May 24; 103 (21): e38268e38268.

AbstractRenal cell carcinoma (RCC) stands among the top 10 malignant neoplasms with the highest fatality rates. It exhibits pronounced heterogeneity and robust metastatic behavior. Patients with RCC may present with solitary or multiple metastatic lesions at various anatomical sites, and their prognoses are contingent upon the site of metastasis. When deliberating the optimal therapeutic approach for a patient, thorough evaluation of significant risk factors such as the feasibility of complete resection, the presence of oligometastases, and the patient's functional and physical condition is imperative. Recognizing the nuanced differences in RCC metastasis to distinct organs proves advantageous in contemplating potential treatment modalities aimed at optimizing survival outcomes. Moreover, discerning the metastatic site holds promise for enhancing risk stratification in individuals with metastatic RCC. This review summarizes the recent data pertaining to the current status of different RCC metastatic sites and elucidates their role in informing clinical management strategies across diverse metastatic locales of RCC.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

10 keywords...

hide…